An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol

Current treatment options for patients with unresectable locally advanced pancreatic cancer (LAPC) include chemotherapy alone or followed by chemoradiation or stereotactic body radiotherapy. However, the prognosis for these patients remains poor, with a median overall survival <12 months. Therefo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhutani, Manoop S., Klapman, Jason B., Tuli, Richard, El-Haddad, Ghassan, Hoffe, Sarah, Wong, Franklin C. L., Chasen, Beth, Fogelman, David R., Lo, Simon K., Nissen, Nicholas N., Hendifar, Andrew E., Varadhachary, Gauri, Katz, Matthew H. G., Erwin, William D., Koay, Eugene J., Tamm, Eric P., Singh, Ben S., Mehta, Rutika, Wolff, Robert A., Soman, Ashish, Cazacu, Irina M., Herman, Joseph M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038730/
https://www.ncbi.nlm.nih.gov/pubmed/31670288
http://dx.doi.org/10.4103/eus.eus_44_19
Descripción
Sumario:Current treatment options for patients with unresectable locally advanced pancreatic cancer (LAPC) include chemotherapy alone or followed by chemoradiation or stereotactic body radiotherapy. However, the prognosis for these patients remains poor, with a median overall survival <12 months. Therefore, novel treatment options are needed. Currently, there is no brachytherapy device approved for pancreatic cancer treatment. Hereby, we present the protocol of a prospective, multicenter, interventional, open-label, single-arm pilot study (OncoPac-1, Clinicaltrial.gov-NCT03076216) aiming to determine the safety and efficacy of Phosphorus-32 when implanted directly into pancreatic tumors using EUS guidance, for patients with unresectable LAPC undergoing chemotherapy (gemcitabine ± nab-paclitaxel).

Ejemplares similares